FOR IMMEDIATE RELEASE:
Vancouver, CANADA – April 19, 2017 – Rhema Health Products Ltd. announced today that it has received approval by Health Canada and a Natural Product Number (NPN) for its much-anticipated Curcumin BDM30™. The product has been selling in the USA, but can now be sold in Canada to brands looking for a research-supported, patent-pending technology that is a revolutionary discovery in anti-inflammatory therapy.
Curcumin BDM30 has the highest level of bisdemethoxycurcumin (BDMC) in the world today. In a standard curcumin extract (95% blend), BDMC exists in extremely low concentrations – between 0.5% – 1.5%. When it is increased to 30% (60 times more than a standard 95% blend), it provides a breakthrough in inflammatory therapy at the genetic level. BDM30 targets and neutralizes a key protein in the nucleus of cells that switches off the production of inflammatory proteins and is more precisely targeted as a curcumin therapy.
BDM30 is also the world’s strongest antioxidant as measured using the oxygen radical absorbance capacity (ORAC) scale, a unit of measurement for antioxidant potential originally developed by the National Institute on Aging. Specifically, it is 125 times stronger than standard curcumin, and 80 times stronger than Astaxanthin, a product previously thought to be the most potent supplement.
Curcumin BDM30™ is based on research by Rhema’s Chief Science Officer, Franco Cavaleri, Ph.D. candidate, who is also the principal research scientist at Biologic Pharmamedical.
“Research shows that BDMC targets inflammation in a unique way and is seven times more effective than standard curcumin,” said Cavaleri. “Instead of trace levels of BDMC in standard curcumin, we can now provide 30% BDMC and dramatically enhance anti-inflammatory relief, which could not be done reliably before using low doses of curcumin.”
This new curcumin research has demonstrated effective modification of survival proteins in difficult-to-treat diseases and specifically the ability to disempower and kill diseased cells. Case studies have shown BDMC demonstrates a faster symptom-resolution time in cases of poorly or uncontrolled inflammation and joint pain when compared to typical curcumin but this will require more formal clinical work to validate. Cavaleri’s research is focused on defining ways to improve clinical and research reliability using curcumin-based drugs as supplements or alternatives to glucocorticoids for glucocorticoid-resistant inflammatory diseases, and to chemotherapy for drug-resistant cancers.